Prostate Cancer - Results from #1580

Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. December 28, 2023

Comparison of Capture Rates of the National Cancer Database Across Race and Ethnicity. December 28, 2023

Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer. December 28, 2023

Utility of prescription-based comorbidity indices for predicting mortality among Australian men with prostate cancer. December 27, 2023

Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer. December 27, 2023

Value-based payment models and management of newly diagnosed prostate cancer. December 27, 2023

Navigating through the Controversies and Emerging Paradigms in Early Detection of Prostate Cancer: Bridging the Gap from Classic RCTs to Modern Population-Based Pilot Programs. December 27, 2023

The Impact of Nutrient Supply on Prostate Cancer Risk Worldwide. December 27, 2023

Outcomes in patients with high- and very high-risk localized prostate cancer treated with definitive IMRT and long-term hormone therapy. December 27, 2023

Evaluation of Recurrent Disease after Radiation Therapy for Patients Considering Local Salvage Therapy: Past vs. Contemporary Management. December 26, 2023

What are the Most Important Objectives of Patients Undergoing Radical Prostatectomy? A Narrative Review. December 26, 2023

Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. December 26, 2023

A Chance Finding of High Grade Prostate Cancer in a 35-Year-Old Male - A Case Report and Outcomes of Robotic Radical Prostatectomy in Young Men with Prostate Cancer. December 26, 2023

Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer. December 26, 2023

Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer. December 26, 2023

ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers. December 26, 2023

Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer. December 26, 2023

First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer. December 25, 2023

Prevalence of bilateral loco-regional spread in unilateral pelvic PSMA PET positive recurrent prostate cancer. December 25, 2023

Blood-based liquid biopsy in advanced prostate cancer. December 25, 2023

Page 80 of 1435